

| | | | | | |
|---|---|----|---|--------------------------|---------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,146 |
| | | | | Filing Date | May 5, 2006 |
| | | | | First Named Inventor | Shyam S. Mohapatra |
| | | | | Art Unit | 1635 |
| | | | | Examiner Name | Richard A. Schnizer |
| Sheet | 1 | of | 5 | Attorney Docket Number | USF.T193XC1 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | U1 | US-2004/0002458 A1 | 01-01-2004 | Seilhamer <i>et al.</i> | All |
| | U2 | US-2005/0266093 A1 | 12-01-2005 | Mohapatra | All |
| | U3 | US-2005/0272650 A1 | 12-08-2005 | Mohapatra | All |
| | U4 | US-2006/0276382 A1 | 12-07-2006 | Mohapatra | All |
| | U5 | US-2007/0265204 A1 | 11-15-2007 | Mohapatra <i>et al.</i> | All |
| | U6 | US-2007/0116767 A1 | 05-24-2007 | Mohapatra | All |
| | U7 | US-2007/0009951 A1 | 01-11-2007 | Mohapatra <i>et al.</i> | All |
| | U8 | US-2008/0023325 A1 | 01-31-2008 | Mohapatra <i>et al.</i> | All |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | F1 | WO 2003/028759 A1 | 04-10-2003 | University of South Florida <i>et al.</i> | All | |
| | F2 | WO 2003/070918 A2 | 08-28-2003 | Ribozyme Pharmaceuticals, Incorporated | All | |
| | F3 | WO 2003/092618 A2 | 11-13-2003 | University of South Florida | All | |
| | F4 | WO 2004/074314 A2 | 08-02-2004 | University of South Florida | All | |
| | F5 | WO 2004/076664 A2 | 09-10-2004 | University of South Florida | All | |
| | F6 | WO 2005/094420 A2 | 10-13-2005 | University of South Florida | All | |
| | F7 | WO 2005/105136 A1 | 11-10-2005 | University of South Florida | All | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/544,146 |
| Filing Date | May 5, 2006 |
| First Named Inventor | Shyam S. Mohapatra |
| Art Unit | 1635 |
| Examiner Name | Richard A. Schnizer |
| Attorney Docket Number | USF.T193XC1 |

Sheet

2

of

5

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
| | | Number - Kind Code ² (if known) | | | |
| | U9 | US-2008/0070858 A1 | 03-20-2008 | Mohapatra | All |
| | U10 | US-2008/0075731 A1 | 03-27-2008 | Mohapatra <i>et al.</i> | All |
| | U11 | US-2008/0100279 A1 | 05-01-2008 | Mohapatra <i>et al.</i> | All |
| | U12 | US-5,931,069 | 11-03-1998 | Barik | All |
| | U13 | US-5,998,602 | 12-07-1999 | Torrence <i>et al.</i> | All |
| | U14 | US-6,489,306 | 12-03-2002 | Mohapatra <i>et al.</i> | All |
| | U15 | US-6,900,299 | 05-31-2005 | Mohapatra <i>et al.</i> | All |
| | U16 | US-7,118,888 | 10-10-2006 | Mohapatra <i>et al.</i> | All |
| | U17 | US-2001/0006951 A1 | 07-05-2001 | Mohapatra <i>et al.</i> | All |
| | U18 | US-2008/0249057 A1 | 10-09-2008 | Mohapatra <i>et al.</i> | All |
| | U19 | US-5,290,540 | 03-01-1994 | Prince <i>et al.</i> | All |
| | U20 | US-5,693,532 | 12-02-1997 | McSwiggen <i>et al.</i> | All |
| | U21 | US-6,586,579 | 06-01-2003 | Huang <i>et al.</i> | All |
| | U22 | US-7,354,908 | 04-08-2008 | Mohapatra <i>et al.</i> | All |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | F8 | WO 2007/127480 A2 | 11-08-2007 | University of South Florida | All | |
| | F9 | WO 2007/127487 A2 | 11-03-2007 | University of South Florida | All | |
| | F10 | | | | | |
| | F11 | | | | | |
| | F12 | | | | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/544,146 |
| Filing Date | May 5, 2006 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1635 |
| Examiner Name | Richard A. Schnizer |
| Attorney Docket Number | USF.T193XC1 |

Sheet 3 of 5

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | R1 | BEHERA, A.K. <i>et al.</i> "Adenovirus-Mediated Interferon γ Gene Therapy for Allergic Asthma: Involvement of Interleukin 12 and STAT4 Signaling" <i>Human Gene Therapy</i> , September 2002, 13:1697-1709. | |
| | R2 | BEHERA, A.K. <i>et al.</i> "2'-5' Oligoadenylate Synthetase Plays a Critical Role in Interferon- γ Inhibition of Respiratory Syncytial Virus Infection of Human Epithelial Cells" <i>The Journal of Biological Chemistry</i> , July 2002, 277(28):25601-25608. | |
| | R3 | BITKO, V. <i>et al.</i> "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses" <i>BMC Microbiology</i> , 2001, 1(34):1-11. | |
| | R4 | BOSSERT, B. <i>et al.</i> "Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV IS Attenuated in Interferon-Competent Bovine Cells" <i>Journal of Virology</i> , May 2002, 76(9):4287-4293. | |
| | R5 | BOSSERT, B. <i>et al.</i> "Nonstructural Proteins NS1 and NS2 of Bovine Respiratory Syncytial Virus Block Activation of Interferon Regulatory Factor 3" <i>Journal of Virology</i> , August 2003, 77(16):8661-8668. | |
| | R6 | DORN, G. <i>et al.</i> "siRNA relieves chronic neuropathic pain" <i>Nucleic Acids Research</i> , 2004, 32(5):e49. | |
| | R7 | HALLAK, L.K. <i>et al.</i> "Iduronic Acid-Containing Glycosaminoglycans on Target Cells Are Required for Efficient Respiratory Syncytial Virus Infection" <i>Virology</i> , 2000, 271:264-275. | |
| | R8 | HELLERMAN, G.R. <i>et al.</i> "Genetic therapy: on the brink of a new future" <i>Genetic Vaccines and Therapy</i> , 2003, 1(1):1-2. | |
| | R9 | JAIRATH, S. <i>et al.</i> "Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides" <i>Antiviral Research</i> , 1997, 33:201-213. | |
| | R10 | JIN, H. <i>et al.</i> "Recombinant Respiratory Syncytial Viruses with Deletions in the NS1, NS2, SH, and M2-2 Genes are Attenuated <i>in Vitro</i> and <i>in Vivo</i> " <i>Virology</i> , 2000, 273:210-218. | |
| | R11 | KUMAR, M. <i>et al.</i> "Intranasal IFN- γ gene transfer protects BALB/c mice against respiratory syncytial virus infection" <i>Vaccine</i> , 2000; 18:558-567. | |
| | R12 | KUMAR, M. <i>et al.</i> "Intranasal Gene Transfer by Chitosan-DNA Nanospheres Protects BALB/c Mice Against Acute Respiratory Syncytial Virus Infection" <i>Human Gene Therapy</i> , August 2002, 13:1415-1425. | |
| | R13 | KUMAR, M. <i>et al.</i> "Chitosan IFN- γ -pDNA Nanoparticle (CIN) Therapy for Allergic Asthma" <i>Genetic Vaccines and Therapy</i> , 2003, 1(3):1-10. | |

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/544,146 |
| Filing Date | May 5, 2006 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1635 |
| Examiner Name | Richard A. Schnizer |
| Attorney Docket Number | USF.T193XC1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | R14 | LEAMAN, D.W. <i>et al.</i> "Targeted Therapy of Respiratory Syncytial Virus in African Green Monkeys by Intranasally Administered 2-5A Antisense" <i>Virology</i> , 2002, 292:70-77. | |
| | R15 | MATSUSE, H. <i>et al.</i> "Recurrent Respiratory Syncytial Virus Infections in Allergen-Sensitized Mice Lead to Persistent Airway Inflammation and Hyperresponsiveness" <i>The Journal of Immunology</i> , 2000, 164:6583-6592. | |
| | R16 | MOHAPATRA, S. "Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus" <i>The Pediatric Infectious Disease Journal</i> , February 2003, 22(2):S100-S104. | |
| | R17 | MURPHY, B.R. "Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics" <i>The Journal of Clinical Investigation</i> , July 2002, 110(1):21-27. | |
| | R18 | LAZAR, I. <i>et al.</i> "Human Metapneumovirus and Severity of Respiratory Syncytial Virus Disease" <i>Emerging Infectious Diseases</i> , July 2004, 10(7):1318-1320, NCBI accession no. M74568. | |
| | R19 | DEPLANCHE, M. <i>et al.</i> "In vivo evidence for quasispecies distributions in the bovine respiratory syncytial virus genome" <i>Journal of General Virology</i> , 2007, 88:1260-1265, NCBI accession no. NC_001989. | |
| | R20 | PAN, W. <i>et al.</i> "Isolation of virus-neutralizing RNAs from a large pool of random sequences" <i>Proc. Natl. Acad. Sci. USA</i> , December 1995, 92:11509-11513. | |
| | R21 | SCHLENDER, J. <i>et al.</i> "Bovine Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Cooperatively Antagonize Alpha/Beta Interferon-Induced Antiviral Response" <i>Journal of Virology</i> , 2000, September 2000, 74(18):8234-8242. | |
| | R22 | SOUTSCHEK, J. <i>et al.</i> "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs" <i>Nature</i> , November 2004, 432:173-178. | |
| | R23 | SPANN, K.M. <i>et al.</i> "Suppression of the Induction of Alpha, Beta, and Gamma Interferons by the NS1 and NS2 Proteins of Human Respiratory Syncytial Virus in Human Epithelial Cells and Macrophages" <i>Journal of Virology</i> , April 2004, 78(8):4363-4369. | |
| | R24 | STEIN, C.A. "The experimental use of antisense oligonucleotides: a guide for the perplexed" <i>The Journal of Clinical Investigation</i> , 2001, 108:641-644. | |
| | R25 | TENG, M.N. <i>et al.</i> "Altered Growth Characteristics of Recombinant Respiratory Syncytial Viruses Which Do Not Produce NS2 Protein" <i>Journal of Virology</i> , January 1999, 73(1):466-473. | |
| | R26 | TENG, M.N. <i>et al.</i> "Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees" <i>Journal of Virology</i> , October 2000, 74(19):9317-9321. | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/544,146 |
| Filing Date | May 5, 2006 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1635 |
| Examiner Name | Richard A. Schnizer |
| Attorney Docket Number | USF.T193XC1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-----------------------|--------------------------|--|----------------|
| | R27 | ZHANG, W. <i>et al.</i> "Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery" <i>Genetic Vaccines and Therapy</i> , 2004, 2(8):1-10. | |
| | R28 | ZHANG, X. <i>et al.</i> "Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia-Reperfusion-induced Lung Apoptosis" <i>The Journal of Biological Chemistry</i> , March 2004, 279(11):10677-10684. | |
| | R29 | ZHAO, C.A. <i>et al.</i> "Inhibition of respiratory syncytial virus replication in cultured cells by RNA-cleaving DNase" <i>Chinese Journal of Pediatrics</i> , 2003, 41(8): 594-597, Medline XP002513933 Database accession No. NLM14744382. | |
| | R30 | REICH, S.J. <i>et al.</i> "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model" <i>Molecular Vision</i> , 2003, 9:210-216. | |
| | R31 | SUBRAMANYA, S. <i>et al.</i> "Targeted Delivery of Small Interfering RNA to Human Dendritic Cells to Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production" <i>Journal of Virology</i> , March 2010, 84(5):2490-2501. | |
| | R32 | | |
| | R33 | | |
| | R34 | | |
| | R35 | | |
| | R36 | | |
| | R37 | | |
| | R38 | | |
| | R39 | | |

Examiner
Signature

/Richard Schnizer/

Date
Considered

04/07/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./